Table 2. Patient GOL040.
| HLA | Epitope location | HXB2 epitope sequence (MHC IC50) | Sampling dates after primary infection (% of RT UDPS variants) | ||||||
| 2.5 months | 3.5 months | 3.5 months | 6.5 months | 6.5 months | 8.5 months | ||||
| RNA | RNA | DNA | RNA | DNA | treatment | DNA | |||
| A*02:01 | p17 | SLYNTVATL | Id | Id | Id | Id | Id | Id | |
| (77–85) | (256.45) | ||||||||
| RT | ALVEICTEM | ALVEICTEM | ALVEICTEM | ALVEICTEM | ALVEICTEM | ALVEICTEM | ALVEICTEM | ||
| (33–41) | (41.72) | (50%) | (100%) | (100%) | (100%) | (100%) | (90%) | ||
| (41.72) | (41.72) | (41.72) | (41.72) | (41.72) | (41.72) | ||||
| ALIEICTEM | AIIEICTEM | ||||||||
| (50%) | (10%) | ||||||||
| (15.61) | (215.37) | ||||||||
| B*08:01 | p17 | ELRSLYNTV | EFRSLYNTV | EFRSLYNTV | EFRSLYNTV | EFRSLYNTV | EFRSLYNTV | EFRSLYNTV | |
| (74–82) | (359.95) | (2264.98) | (2264.98) | (2264.98) | (2264.98) | (2264.98) | (2264.98) | ||
| p24 | EIYKRWII | Id | Id | Id | Id | Id | Id | ||
| (128–135) | (257.38) | ||||||||
| RT | GPKVKQWPL | GPKVKQWPL | GPKVKQWPL | GPKVKQWPL | GPKVKQWPL | GPKVKQWPL | GPKVKQWPL | ||
| (18–26) | (72.58) | (100%) | (100%) | (100%) | (100%) | (100%) | (100%) | ||
| (72.58) | (72.58) | (72.58) | (72.58) | (72.58) | (72.58) | ||||
| Nef | FLKEKGGL | Id | Id | Id | Id | Id | Id | ||
| (90–97) | (228.50) | ||||||||